glipizide has been researched along with Fasting Hypoglycemia in 76 studies
Glipizide: An oral hypoglycemic agent which is rapidly absorbed and completely metabolized.
glipizide : An N-sulfonylurea that is glyburide in which the (5-chloro-2-methoxybenzoyl group is replaced by a (5-methylpyrazin-2-yl)carbonyl group. An oral hypoglycemic agent, it is used in the treatment of type 2 diabetes mellitus.
Fasting Hypoglycemia: HYPOGLYCEMIA expressed in the postabsorptive state, after prolonged FASTING, or an overnight fast.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Saxagliptin + metformin was associated with fewer patients reporting hypoglycemia and fewer and less severe hypoglycemic events in those experiencing hypoglycemia compared with glipizide + metformin." | 9.19 | Saxagliptin versus glipizide as add-on therapy to metformin: assessment of hypoglycemia. ( Minervini, G; Mintz, ML, 2014) |
| " glipizide) and serious hypoglycemia." | 7.85 | Sentinel Modular Program for Propensity Score-Matched Cohort Analyses: Application to Glyburide, Glipizide, and Serious Hypoglycemia. ( Archdeacon, P; Axtman, S; Carnahan, RM; Cavagnaro, E; Chrischilles, EA; Fuller, C; Gagne, JJ; Hampp, C; Hennessy, S; Iyer, A; Leonard, CE; Panozzo, CA; Toh, S; Wang, SV; Woodworth, TS; Zhou, M, 2017) |
| "In pre-specified analyses adjusting for the most recently measured HbA(1c) value, there was a substantial reduction in risk for confirmed hypoglycemia with sitagliptin compared to glipizide when added to ongoing metformin therapy in patients with T2DM." | 7.78 | Lower risk of hypoglycemia with sitagliptin compared to glipizide when either is added to metformin therapy: a pre-specified analysis adjusting for the most recently measured HbA(1c) value. ( Davies, MJ; Ferrante, SA; Goldstein, BJ; Kaufman, KD; Krobot, KJ; Meininger, GE; Seck, T; Williams-Herman, D, 2012) |
| "To (a) identify whether hemoglobin A1c remained equivalent in patients converted from glyburide to glipizide, (b) evaluate the prevalence of hypoglycemia during treatment with glyburide or glipizide, (c) compare change in glycemic control for renally impaired versus nonimpaired patients, and (d) analyze dosage conversion ratios selected by providers and measures of patient follow-up after conversion including time until A1c measurement and number of glipizide dose titrations." | 7.77 | Glycemic control and hypoglycemia in Veterans Health Administration patients converted from glyburide to glipizide. ( Cantrell, M; Egge, JA; Shaw, RF; Skoff, RA; Waterbury, NV, 2011) |
| "The objective of this study was to evaluate whether orally administered anti-infectives increase the risk of severe hypoglycemia in users of glipizide or glyburide." | 7.76 | Anti-infectives and the risk of severe hypoglycemia in users of glipizide or glyburide. ( Bilker, WB; Brensinger, CM; Hennessy, S; Schelleman, H; Wan, F, 2010) |
| "Patients presenting with hypoglycemia resulting from therapeutic sulfonylurea use demonstrate similar insulin and C-peptide levels as has previously been published among patients who presented with presumed overdose." | 7.76 | Quantitative insulin and C-peptide levels among ED patients with sulfonylurea-induced hypoglycemia-a prospective case series. ( Aguilera, E; Fasano, CJ; Heard, K; O'Malley, GF; Rowden, AK, 2010) |
| "A case of hypoglycemia associated with levofloxacin is reported." | 7.75 | Hypoglycemia associated with the use of levofloxacin. ( Garber, SM; Miller, SM; Pound, MW, 2009) |
| "This is the first report to describe the delayed onset of hypoglycemia in a child after ingestion of one tablet of glipizide." | 7.70 | Delayed hypoglycemia in a child after ingestion of a single glipizide tablet. ( Capes, KF; Szlatenyi, CS; Wang, RY, 1998) |
| "The hypoglycemia was severe and required multiple dextrose boluses in addition to continuous dextrose infusion for 36 hours." | 5.35 | Extended-release glipizide overdose presenting with delayed hypoglycemia and treated with subcutaneous octreotide. ( Abramson, E; Pelavin, PI; Pon, S; Vogiatzi, MG, 2009) |
| " This case suggests that, when TMP/SMX is combined with glipizide, patients should be closely monitored, especially those at high risk for hypoglycemia." | 5.28 | Symptomatic hypoglycemia secondary to a glipizide-trimethoprim/sulfamethoxazole drug interaction. ( Dobmeier, ME; Johnson, JF, 1990) |
| "In patients completing 4 years of treatment, dapagliflozin was well tolerated and associated with sustained glycaemic efficacy and greater reductions in body weight and SBP versus glipizide." | 5.20 | Long-term glycaemic response and tolerability of dapagliflozin versus a sulphonylurea as add-on therapy to metformin in patients with type 2 diabetes: 4-year data. ( Del Prato, S; Durán-Garcia, S; Maffei, L; Nauck, M; Parikh, S; Rohwedder, K; Theuerkauf, A, 2015) |
| "Saxagliptin + metformin was associated with fewer patients reporting hypoglycemia and fewer and less severe hypoglycemic events in those experiencing hypoglycemia compared with glipizide + metformin." | 5.19 | Saxagliptin versus glipizide as add-on therapy to metformin: assessment of hypoglycemia. ( Minervini, G; Mintz, ML, 2014) |
| "Alogliptin monotherapy maintained glycaemic control comparable to that of glipizide in elderly patients with T2DM over 1 year of treatment, with substantially lower risk of hypoglycaemia and without weight gain." | 5.17 | Alogliptin versus glipizide monotherapy in elderly type 2 diabetes mellitus patients with mild hyperglycaemia: a prospective, double-blind, randomized, 1-year study. ( Fleck, P; Rosenstock, J; Wilson, C, 2013) |
| " glipizide) and serious hypoglycemia." | 3.85 | Sentinel Modular Program for Propensity Score-Matched Cohort Analyses: Application to Glyburide, Glipizide, and Serious Hypoglycemia. ( Archdeacon, P; Axtman, S; Carnahan, RM; Cavagnaro, E; Chrischilles, EA; Fuller, C; Gagne, JJ; Hampp, C; Hennessy, S; Iyer, A; Leonard, CE; Panozzo, CA; Toh, S; Wang, SV; Woodworth, TS; Zhou, M, 2017) |
| "In quarters with glipizide/glimepiride use, hospital admissions or emergency department visits for hypoglycemia were more common in person quarters with concurrent warfarin use compared with quarters without warfarin use (294/416,479 v 1903/3,938,939; adjusted odds ratio 1." | 3.81 | Association between use of warfarin with common sulfonylureas and serious hypoglycemic events: retrospective cohort analysis. ( Goldman, DP; Gong, C; Jena, AB; Peters, A; Romley, JA; Williams, B, 2015) |
| "To determine the risk of hypoglycemia and associated costs in older patients prescribed glipizide or glyburide who fill a prescription for an antimicrobial drug." | 3.80 | Hypoglycemia after antimicrobial drug prescription for older patients using sulfonylureas. ( Goodwin, JS; Kuo, YF; Lin, YL; Parekh, TM; Raji, M; Tan, A, 2014) |
| "A 17-month-old child presented to the emergency department with marked hypoglycemia, cerebral edema, and persistent seizures after ingestion of an unknown amount of glipizide." | 3.79 | Continuous octreotide infusion for sulfonylurea-induced hypoglycemia in a toddler. ( Czaja, A; Davidson, J; Llamado, R; Stence, N, 2013) |
| "Overall, 19% of patients who received a sulfonylurea experienced at least one episode of hypoglycemia: 22% receiving glyburide, 19% receiving glimepiride, and 16% receiving glipizide." | 3.78 | Hypoglycemia in hospitalized patients treated with sulfonylureas. ( Coley, KC; Deusenberry, CM; Donihi, AC; Korytkowski, MT, 2012) |
| "In pre-specified analyses adjusting for the most recently measured HbA(1c) value, there was a substantial reduction in risk for confirmed hypoglycemia with sitagliptin compared to glipizide when added to ongoing metformin therapy in patients with T2DM." | 3.78 | Lower risk of hypoglycemia with sitagliptin compared to glipizide when either is added to metformin therapy: a pre-specified analysis adjusting for the most recently measured HbA(1c) value. ( Davies, MJ; Ferrante, SA; Goldstein, BJ; Kaufman, KD; Krobot, KJ; Meininger, GE; Seck, T; Williams-Herman, D, 2012) |
| "To (a) identify whether hemoglobin A1c remained equivalent in patients converted from glyburide to glipizide, (b) evaluate the prevalence of hypoglycemia during treatment with glyburide or glipizide, (c) compare change in glycemic control for renally impaired versus nonimpaired patients, and (d) analyze dosage conversion ratios selected by providers and measures of patient follow-up after conversion including time until A1c measurement and number of glipizide dose titrations." | 3.77 | Glycemic control and hypoglycemia in Veterans Health Administration patients converted from glyburide to glipizide. ( Cantrell, M; Egge, JA; Shaw, RF; Skoff, RA; Waterbury, NV, 2011) |
| "Patients presenting with hypoglycemia resulting from therapeutic sulfonylurea use demonstrate similar insulin and C-peptide levels as has previously been published among patients who presented with presumed overdose." | 3.76 | Quantitative insulin and C-peptide levels among ED patients with sulfonylurea-induced hypoglycemia-a prospective case series. ( Aguilera, E; Fasano, CJ; Heard, K; O'Malley, GF; Rowden, AK, 2010) |
| "The objective of this study was to evaluate whether orally administered anti-infectives increase the risk of severe hypoglycemia in users of glipizide or glyburide." | 3.76 | Anti-infectives and the risk of severe hypoglycemia in users of glipizide or glyburide. ( Bilker, WB; Brensinger, CM; Hennessy, S; Schelleman, H; Wan, F, 2010) |
| "A case of hypoglycemia associated with levofloxacin is reported." | 3.75 | Hypoglycemia associated with the use of levofloxacin. ( Garber, SM; Miller, SM; Pound, MW, 2009) |
| "This is the first report to describe the delayed onset of hypoglycemia in a child after ingestion of one tablet of glipizide." | 3.70 | Delayed hypoglycemia in a child after ingestion of a single glipizide tablet. ( Capes, KF; Szlatenyi, CS; Wang, RY, 1998) |
| " Adverse events (AE) and hypoglycemia were monitored." | 2.79 | Saxagliptin efficacy and safety in patients with type 2 diabetes mellitus stratified by cardiovascular disease history and cardiovascular risk factors: analysis of 3 clinical trials. ( Bryzinski, B; Cook, W; Hirshberg, B; Minervini, G, 2014) |
| "glipizide was associated with a significantly smaller proportion of patients with hypoglycaemic events (3." | 2.75 | Saxagliptin is non-inferior to glipizide in patients with type 2 diabetes mellitus inadequately controlled on metformin alone: a 52-week randomised controlled trial. ( Eriksson, J; Gallwitz, B; Gause-Nilsson, I; Göke, B; Hellqvist, A, 2010) |
| "No hypoglycemia was observed during 156 fasting studies." | 2.69 | A prospective trial of risk factors for sulfonylurea-induced hypoglycemia in type 2 diabetes mellitus. ( Burge, MR; Fischette, C; Qualls, CR; Schade, DS; Schmitz-Fiorentino, K, 1998) |
| " We compared the effects of three SU medications and initial SU doses on adverse glycemic and cardiovascular events among NH residents." | 1.91 | Comparative safety of sulfonylureas among U.S. nursing home residents. ( Berry, SD; Hayes, KN; Munshi, MN; Riester, MR; Zullo, AR, 2023) |
| "Serious hypoglycemia is a major adverse event associated with insulin secretagogues." | 1.72 | Angiotensin-Converting Enzyme Inhibitors Used Concomitantly with Insulin Secretagogues and the Risk of Serious Hypoglycemia. ( Bilker, WB; Brensinger, CM; Flory, JH; Hee Nam, Y; Hennessy, S; Leonard, CE, 2022) |
| "Hypoglycemia was defined as hospital admission or an emergency department visit for hypoglycemia or as an outpatient blood glucose <60 mg/dL." | 1.48 | Risk of Hypoglycemia Following Hospital Discharge in Patients With Diabetes and Acute Kidney Injury. ( Abdel-Kader, K; Greevy, RA; Griffin, MR; Horner, J; Hung, AM; Ikizler, TA; Matheny, ME; Parr, SK; Perkins, AM; Roumie, CL; Siew, ED; Speroff, T; Wilson, OD, 2018) |
| " We aimed to systematically screen for drugs that interact with the five most commonly used secretagogues-glipizide, glyburide, glimepiride, repaglinide, and nateglinide-to cause serious hypoglycemia." | 1.46 | Biomedical Informatics Approaches to Identifying Drug-Drug Interactions: Application to Insulin Secretagogues. ( Bilker, WB; Brensinger, CM; Chiang, C; Han, X; Hennessy, S; Leonard, CE; Li, L, 2017) |
| "Hypoglycemia is common after accidental sulfonylurea exposures." | 1.37 | Hypoglycemia after accidental pediatric sulfonylurea ingestions. ( Burns, BD; Levine, M; Lovecchio, F; Pizon, AF; Riley, BD; Ruha, AM; Thomas, SH, 2011) |
| "The hypoglycemia was severe and required multiple dextrose boluses in addition to continuous dextrose infusion for 36 hours." | 1.35 | Extended-release glipizide overdose presenting with delayed hypoglycemia and treated with subcutaneous octreotide. ( Abramson, E; Pelavin, PI; Pon, S; Vogiatzi, MG, 2009) |
| "A total of 400 patients with type 2 diabetes, who were > or = 35 years old and who had been treated with metformin and a sulphonylurea for at least 6 months, completed questionnaires during their usual primary care office visit." | 1.35 | Hypoglycaemia in patients with type 2 diabetes treated with a combination of metformin and sulphonylurea therapy in France. ( Krishnarajah, G; Lyu, R; Mavros, P; Vexiau, P; Yin, D, 2008) |
| "A diabetic patient with chronic renal failure who developed recurrent and prolonged episodes of hypoglycemia associated with use of sulfonylurea agent is presented here." | 1.32 | Use of octreotide to treat prolonged sulfonylurea-induced hypoglycemia in a patient with chronic renal failure. ( Edeki, T; Nzerue, CM; Thomas, J; Volcy, J, 2003) |
| "Hypoglycemia was defined as blood glucose (BG) concentration < 60 mg/dl." | 1.30 | Prospective multicenter study of sulfonylurea ingestion in children. ( Anderson, BD; Anderson, DL; Fenn, J; Gorman, SE; Krenzelok, EP; Muir, SJ; Rodgers, GC; Rose, SR; Spiller, HA; Villalobos, D, 1997) |
| " This case suggests that, when TMP/SMX is combined with glipizide, patients should be closely monitored, especially those at high risk for hypoglycemia." | 1.28 | Symptomatic hypoglycemia secondary to a glipizide-trimethoprim/sulfamethoxazole drug interaction. ( Dobmeier, ME; Johnson, JF, 1990) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 8 (10.53) | 18.7374 |
| 1990's | 19 (25.00) | 18.2507 |
| 2000's | 14 (18.42) | 29.6817 |
| 2010's | 30 (39.47) | 24.3611 |
| 2020's | 5 (6.58) | 2.80 |
| Authors | Studies |
|---|---|
| Volke, V | 1 |
| Katus, U | 1 |
| Johannson, A | 1 |
| Toompere, K | 1 |
| Heinla, K | 1 |
| Rünkorg, K | 1 |
| Uusküla, A | 1 |
| Zullo, AR | 2 |
| Riester, MR | 2 |
| Hayes, KN | 2 |
| Munshi, MN | 2 |
| Berry, SD | 2 |
| Chmieliauskaite, M | 1 |
| Grosh, MD | 1 |
| Syed, A | 1 |
| Pinto, A | 1 |
| Chen, L | 1 |
| Li, JH | 1 |
| Kaur, V | 1 |
| Muhammad, A | 1 |
| Fernandez, M | 1 |
| Hudson, MS | 1 |
| Goldfine, AB | 2 |
| Florez, JC | 1 |
| Hee Nam, Y | 1 |
| Brensinger, CM | 6 |
| Bilker, WB | 6 |
| Flory, JH | 3 |
| Leonard, CE | 5 |
| Hennessy, S | 7 |
| Zhou, M | 1 |
| Wang, SV | 1 |
| Gagne, JJ | 3 |
| Fuller, C | 1 |
| Hampp, C | 1 |
| Archdeacon, P | 1 |
| Toh, S | 1 |
| Iyer, A | 1 |
| Woodworth, TS | 1 |
| Cavagnaro, E | 1 |
| Panozzo, CA | 1 |
| Axtman, S | 1 |
| Carnahan, RM | 1 |
| Chrischilles, EA | 1 |
| Douros, A | 1 |
| Yin, H | 1 |
| Yu, OHY | 1 |
| Filion, KB | 1 |
| Azoulay, L | 1 |
| Suissa, S | 1 |
| Hung, AM | 1 |
| Siew, ED | 1 |
| Wilson, OD | 1 |
| Perkins, AM | 1 |
| Greevy, RA | 1 |
| Horner, J | 1 |
| Abdel-Kader, K | 1 |
| Parr, SK | 1 |
| Roumie, CL | 1 |
| Griffin, MR | 1 |
| Ikizler, TA | 1 |
| Speroff, T | 1 |
| Matheny, ME | 1 |
| Aquilante, CL | 1 |
| Boudreau, DM | 1 |
| Deo, R | 1 |
| Mangaali, MJ | 1 |
| Beardmore, D | 1 |
| Rosenstock, J | 2 |
| Wilson, C | 2 |
| Fleck, P | 2 |
| Göke, B | 2 |
| Gallwitz, B | 2 |
| Eriksson, JG | 1 |
| Hellqvist, Å | 2 |
| Gause-Nilsson, I | 2 |
| Llamado, R | 1 |
| Czaja, A | 1 |
| Stence, N | 1 |
| Davidson, J | 1 |
| Mintz, ML | 1 |
| Minervini, G | 2 |
| Maffioli, P | 1 |
| Derosa, G | 1 |
| Schelleman, H | 2 |
| Han, X | 3 |
| Quinney, SK | 1 |
| Flockhart, DA | 2 |
| Li, L | 2 |
| Tan, A | 2 |
| Holmes, HM | 1 |
| Kuo, YF | 2 |
| Raji, MA | 1 |
| Goodwin, JS | 2 |
| Nauck, MA | 1 |
| Del Prato, S | 3 |
| Durán-García, S | 2 |
| Rohwedder, K | 2 |
| Langkilde, AM | 1 |
| Sugg, J | 1 |
| Parikh, SJ | 1 |
| Camisasca, R | 1 |
| Parekh, TM | 1 |
| Raji, M | 1 |
| Lin, YL | 1 |
| Cook, W | 1 |
| Bryzinski, B | 1 |
| Hirshberg, B | 1 |
| Nauck, M | 1 |
| Maffei, L | 1 |
| Theuerkauf, A | 1 |
| Parikh, S | 1 |
| Cardillo, S | 1 |
| Romley, JA | 1 |
| Gong, C | 1 |
| Jena, AB | 1 |
| Goldman, DP | 1 |
| Williams, B | 1 |
| Peters, A | 1 |
| Chiang, C | 1 |
| Pelavin, PI | 1 |
| Abramson, E | 1 |
| Pon, S | 1 |
| Vogiatzi, MG | 1 |
| Garber, SM | 1 |
| Pound, MW | 1 |
| Miller, SM | 1 |
| Kelesidis, T | 1 |
| Canseco, E | 1 |
| Osterhoudt, KC | 2 |
| Calello, DP | 2 |
| Wan, F | 1 |
| Eriksson, J | 1 |
| Fasano, CJ | 1 |
| Rowden, AK | 1 |
| O'Malley, GF | 1 |
| Aguilera, E | 1 |
| Heard, K | 1 |
| Seck, TL | 1 |
| Engel, SS | 1 |
| Williams-Herman, DE | 1 |
| Sisk, CM | 1 |
| Golm, GT | 1 |
| Wang, H | 1 |
| Kaufman, KD | 2 |
| Goldstein, BJ | 2 |
| Levine, M | 1 |
| Ruha, AM | 1 |
| Lovecchio, F | 1 |
| Riley, BD | 1 |
| Pizon, AF | 1 |
| Burns, BD | 1 |
| Thomas, SH | 1 |
| Skoff, RA | 1 |
| Waterbury, NV | 1 |
| Shaw, RF | 1 |
| Egge, JA | 1 |
| Cantrell, M | 1 |
| Gil, E | 1 |
| Mintsman, I | 1 |
| Wolfowitz, E | 1 |
| Deusenberry, CM | 1 |
| Coley, KC | 1 |
| Korytkowski, MT | 1 |
| Donihi, AC | 1 |
| Krobot, KJ | 1 |
| Ferrante, SA | 1 |
| Davies, MJ | 1 |
| Seck, T | 1 |
| Meininger, GE | 1 |
| Williams-Herman, D | 1 |
| Bussing, R | 1 |
| Gende, A | 1 |
| Nzerue, CM | 1 |
| Thomas, J | 1 |
| Volcy, J | 1 |
| Edeki, T | 1 |
| Cakir, M | 1 |
| Akin, M | 1 |
| Karayalcin, U | 1 |
| Aldhahi, W | 1 |
| Armstrong, J | 1 |
| Bouche, C | 1 |
| Carr, RD | 1 |
| Moses, A | 1 |
| Feinglos, M | 1 |
| Dailey, G | 1 |
| Cefalu, W | 1 |
| Osei, K | 1 |
| Tayek, J | 1 |
| Canovatchel, W | 1 |
| Chaiken, R | 1 |
| Kourides, I | 1 |
| Mutalik, S | 1 |
| Udupa, N | 1 |
| Kumar, S | 1 |
| Agarwal, S | 1 |
| Subramanian, G | 1 |
| Ranjith, AK | 1 |
| Singh, R | 1 |
| Soderstrom, J | 1 |
| Murray, L | 1 |
| Daly, FF | 1 |
| Little, M | 1 |
| Kelly, A | 1 |
| Vexiau, P | 1 |
| Mavros, P | 1 |
| Krishnarajah, G | 1 |
| Lyu, R | 1 |
| Yin, D | 1 |
| Loubatieres-Mariani, MM | 1 |
| Blohmé, G | 1 |
| Fahlén, M | 1 |
| Branegård, BU | 1 |
| Mårin, P | 1 |
| Sener, A | 2 |
| Akkan, AG | 1 |
| Malaisse, WJ | 2 |
| Gillet, C | 1 |
| Verhelst, J | 1 |
| DeBoeck, K | 1 |
| Mahler, C | 1 |
| During, MJ | 1 |
| Leone, P | 1 |
| Davis, KE | 1 |
| Kerr, D | 1 |
| Sherwin, RS | 1 |
| Riddle, MC | 1 |
| McDaniel, PA | 1 |
| Tive, LA | 1 |
| van Staa, T | 1 |
| Abenhaim, L | 1 |
| Monette, J | 1 |
| Spiller, HA | 1 |
| Villalobos, D | 1 |
| Krenzelok, EP | 1 |
| Anderson, BD | 1 |
| Gorman, SE | 1 |
| Rose, SR | 1 |
| Fenn, J | 1 |
| Anderson, DL | 1 |
| Muir, SJ | 1 |
| Rodgers, GC | 1 |
| Roche, ME | 1 |
| Oda, RP | 1 |
| Lawson, GM | 1 |
| Landers, JP | 1 |
| Burge, MR | 1 |
| Schmitz-Fiorentino, K | 1 |
| Fischette, C | 1 |
| Qualls, CR | 1 |
| Schade, DS | 1 |
| Shorr, RI | 1 |
| Gambassi, G | 1 |
| Carbonin, P | 1 |
| Bernabei, R | 1 |
| Szlatenyi, CS | 1 |
| Capes, KF | 1 |
| Wang, RY | 1 |
| Hutchinson, C | 1 |
| Peppard, C | 1 |
| Mullins, ME | 1 |
| Warden, CR | 1 |
| Horowitz, BZ | 1 |
| Robertson, WO | 1 |
| Slover-Zipf, J | 1 |
| Martin, G | 1 |
| Rand, J | 1 |
| Farr, MJ | 1 |
| Greenwood, RH | 1 |
| Mahler, RF | 1 |
| Hales, CN | 1 |
| Cryer, PE | 1 |
| Asplund, K | 1 |
| Wiholm, BE | 1 |
| Lundman, B | 1 |
| Shenfield, GM | 1 |
| Boutagy, JS | 1 |
| Webb, C | 1 |
| Johnson, JF | 1 |
| Dobmeier, ME | 1 |
| Wensing, G | 1 |
| McKillop, G | 1 |
| Fallon, M | 1 |
| Slater, SD | 1 |
| Meisel, A | 1 |
| Raskin, P | 1 |
| Gerich, JE | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Study to Understand the Genetics of the Acute Response to Metformin and Glipizide in Humans[NCT01762046] | Phase 1 | 1,000 participants (Anticipated) | Interventional | 2008-01-31 | Active, not recruiting | ||
| A 52-Week International, Multi-centre, Randomized, Parallel-group, Double-blind, Active-controlled, Phase III Study With a 52-Week Extension Period to Evaluate the Safety and Efficacy of Saxagliptin in Combination With Metformin Compared With Sulphonylure[NCT00575588] | Phase 3 | 891 participants (Actual) | Interventional | 2007-12-31 | Completed | ||
| A Study of the Effects of Dapagliflozin on Ambulatory Aortic Pressure, Arterial Stiffness and Urine Albumin Excretion in Patients With Type 2 Diabetes[NCT02887677] | Phase 4 | 85 participants (Actual) | Interventional | 2016-10-31 | Terminated (stopped due to On February 2019 Astra-Zeneca Greece decided to stop the financial support of the study.) | ||
| Effectiveness of the Treatment With Dapagliflozin and Metformin Compared to Metformin Monotherapy for Weight Loss on Diabetic and Prediabetic Patients With Obesity Class III[NCT03968224] | Phase 2/Phase 3 | 90 participants (Anticipated) | Interventional | 2018-07-07 | Recruiting | ||
| A Multicenter, Randomized, Double-Blind, Phase 3 Trial to Evaluate the Efficacy and Safety of Saxagliptin Added to Insulin Monotherapy or to Insulin in Combination With Metformin in Subjects With Type 2 Diabetes Who Have Inadequate Glycemic Control on Ins[NCT00757588] | Phase 3 | 455 participants (Actual) | Interventional | 2008-11-30 | Completed | ||
| A Multicenter, Randomized, Double-Blind Active-Controlled, Phase 3 Trial to Evaluate the Efficacy and Safety of Saxagliptin in Combination With Metformin IR as Initial Therapy Compared to Saxagliptin Monotherapy and to Metformin IR Monotherapy in Subjects[NCT00327015] | Phase 3 | 1,306 participants (Actual) | Interventional | 2006-05-31 | Completed | ||
| Prospective, Parallel Goups Study, Aimed to Evaluating Possible Benefits of the Treatment of New Generation Hypoglycaemic Drugs Compared to Sulphonylureas for the Tratment of Type 2 Diabetes Mellitus[NCT04272359] | 138 participants (Anticipated) | Observational [Patient Registry] | 2019-05-06 | Recruiting | |||
| A Multicenter, Double-Blind, Randomized Study to Evaluate the Safety and Efficacy of the Addition of MK0431 Compared With Sulfonylurea Therapy in Patients With Type 2 Diabetes With Inadequate Glycemic Control on Metformin Monotherapy[NCT00094770] | Phase 3 | 1,172 participants (Actual) | Interventional | 2004-09-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Mean slopes of regression of change from Week 24 to Week 104 in HbA1c for saxagliptin added on to metformin versus glipizide added on to metformin (Full Analysis Set) achieved by fitting a mixed model with subject specific slopes for the time effect (weeks on randomized treatment was utilized). This analysis gives an assessment of the durability of the HbA1c effect. (NCT00575588)
Timeframe: Week 24 to Week 104
| Intervention | Percent (Mean) |
|---|---|
| Saxagliptin + Metformin | 0.0041 |
| Glipizide + Metformin | 0.0076 |
Mean slopes of regression of change from Week 24 to Week 52 in HbA1c for saxagliptin added on to metformin versus glipizide added on to metformin (Per Protocol Analysis Set) achieved by fitting a mixed model with subject specific slopes for the time effect (weeks on randomized treatment was utilized). This analysis gives an assessment of the durability of the HbA1c effect. (NCT00575588)
Timeframe: Week 24 to Week 52
| Intervention | Percent (Mean) |
|---|---|
| Saxagliptin + Metformin | 0.001 |
| Glipizide + Metformin | 0.004 |
Proportion of participants reporting at least one episode of any hypoglycaemic event for saxagliptin added on to metformin versus glipizide added on to metformin over 104 weeks (Safety Analysis Set) (NCT00575588)
Timeframe: Baseline, Week 104
| Intervention | Percentage of Participants (Number) |
|---|---|
| Saxagliptin + Metformin | 3.5 |
| Glipizide + Metformin | 38.4 |
Proportion of participants reporting at least one episode of any hypoglycaemic event for saxagliptin added on to metformin versus glipizide added on to metformin over 52 weeks (Safety Analysis Set) (NCT00575588)
Timeframe: From Baseline to Week 52
| Intervention | Percentage of Participants (Number) |
|---|---|
| Saxagliptin + Metformin | 3 |
| Glipizide + Metformin | 36.3 |
Adjusted mean change from baseline in Body Weight achieved with saxagliptin added on to metformin versus glipizide added on to metformin at Week 104. Body Weight is a continuous measure, the change from baseline for each participant is calculated as the Week 104 value minus the baseline value. (NCT00575588)
Timeframe: Baseline, Week 104
| Intervention | kilograms (Mean) | ||
|---|---|---|---|
| Baseline | Week 104 | Adjusted Change from Baseline to Week 104 | |
| Glipizide + Metformin | 88.57 | 89.80 | 1.29 |
| Saxagliptin + Metformin | 88.69 | 87.47 | -1.47 |
Adjusted mean change from baseline in Body Weight achieved with saxagliptin added on to metformin versus glipizide added on to metformin at Week 52 (Safety Analysis Set). Body Weight is a continuous measure, the change from baseline for each participant is calculated as the Week 52 (LOCF) value minus the baseline value. (NCT00575588)
Timeframe: Baseline, Week 52 (Last Observation Carried Forward)
| Intervention | kilogram (Mean) | ||
|---|---|---|---|
| Baseline | Week 52 | Adjusted Change from Baseline to Week 52 | |
| Glipizide + Metformin | 88.6 | 89.7 | 1.1 |
| Saxagliptin + Metformin | 88.7 | 87.6 | -1.1 |
Adjusted mean change from baseline in HbA1c achieved with saxagliptin added on to metformin versus glipizide added on to metformin at Week 104 (Full Analysis Set). HbA1c is a continuous measure, the change from baseline for each participant is calculated as the Week 104 value minus the baseline value. (NCT00575588)
Timeframe: Baseline, Week 104
| Intervention | Percent (Mean) | ||
|---|---|---|---|
| Baseline | Week 104 | Adjusted Change from Baseline to Week 104 | |
| Glipizide + Metformin | 7.65 | 7.27 | -0.35 |
| Saxagliptin + Metformin | 7.65 | 7.27 | -0.41 |
Adjusted mean change from baseline in HbA1c achieved with saxagliptin added on to metformin versus glipizide added on to metformin at Week 52 (Per Protocol Analysis Set). HbA1c is a continuous measure, the change from baseline for each participant is calculated as the Week 52 value minus the baseline value. (NCT00575588)
Timeframe: Baseline to 52 Weeks
| Intervention | Percent (Mean) | ||
|---|---|---|---|
| Baseline | Week 52 | Adjusted Change from Baseline to Week 52 | |
| Glipizide + Metformin | 7.53 | 6.71 | -0.80 |
| Saxagliptin + Metformin | 7.46 | 6.74 | -0.74 |
Change from baseline: post-pre. Adjusted for baseline (value and metformin use). ANCOVA model: difference between week t and baseline values=baseline values + treatment + metformin use (NCT00757588)
Timeframe: Baseline to Week 24
| Intervention | Percentage of change (Mean) |
|---|---|
| Saxagliptin, 5 mg + Insulin | -0.73 |
| Placebo + Insulin | -0.32 |
An MTT is a 2-part test that measures glucose and insulin levels after an overnight fast and before ingesting a meal consisting of a nutritional drink and power bar and again at prespecified times (30, 60, 120, and 180 minutes) after the start of ingestion of the meal. (NCT00757588)
Timeframe: Baseline to Week 24
| Intervention | mg/dL (Mean) |
|---|---|
| Saxagliptin, 5 mg + Insulin | -27.2 |
| Placebo + Insulin | -4.2 |
(NCT00757588)
Timeframe: Baseline to Week 24
| Intervention | mg/dL (Mean) |
|---|---|
| Saxagliptin, 5 mg + Insulin | -10.1 |
| Placebo + Insulin | -6.1 |
Based on information recorded in the participant's daily diary. The MTDDI was calculated at every visit using the values patients recorded since the last regularly scheduled visit (minimum of 80% of days with a value). At every visit, the MTDDI was compared with the participant's baseline MTDDI (measured during a 4-week lead-in period) to identify any changes in insulin use at that visit compared with insulin use at baseline. (NCT00757588)
Timeframe: Baseline to Week 24
| Intervention | Units (Mean) |
|---|---|
| Saxagliptin, 5 mg + Insulin | 1.71 |
| Placebo + Insulin | 5.01 |
An MTT is a 2-part test that measures glucose and insulin levels after an overnight fast and before ingesting a meal consisting of a nutritional drink and power bar and again at prespecified times (30, 60, 120, and 180 minutes) after the start of ingestion of the meal (NCT00757588)
Timeframe: Baseline to Week 24
| Intervention | mg*min/dL (Mean) |
|---|---|
| Saxagliptin, 5 mg + Insulin | -4548.5 |
| Placebo + Insulin | -718.8 |
"ECG abnormalities included those in nonspecific other categories (Other nonspecific ST/T, Other intraventricular conduction defect, Other, and Other rhythm abnormalities)and nonspecific findings, such as sinus bradycardia, sinus arrythmia, sinus tachycardia, poor R-wave progression, and ventricular premature contractions." (NCT00757588)
Timeframe: Baseline to Week 52
| Intervention | Participants (Number) |
|---|---|
| Saxagliptin, 5 mg + Insulin | 15 |
| Placebo + Insulin | 11 |
Therapeutic glycemic response is defined as an A1C<7%. Significance was not interpreted with a p value. (NCT00757588)
Timeframe: Baseline to Week 24
| Intervention | Percentage of participants (Number) |
|---|---|
| Saxagliptin, 5 mg + Insulin | 17.3 |
| Placebo + Insulin | 6.7 |
(NCT00757588)
Timeframe: Baseline to Weeks 2, 4, 6, 8, 12, 16, 20, 24, 28, 36, 44, and 52
| Intervention | Beats per minute (Number) | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Week 2 (n=294, 147) | Week 4 (n=293, 144) | Week 6 (n=280, 141) | Week 8 (n=290, 142) | Week 12 (n=286, 144) | Week 16 (n=278, 139) | Week 20 (n=276, 137) | Week 24 (n=273, 134) | Week 28 (n=264, 132) | Week 36 (n=261, 129) | Week 44 (n=250, 125) | Week 52 (n=246, 125) | |
| Placebo + Insulin | -0.7 | -1.0 | -0.9 | -0.7 | 0.2 | -0.6 | 0.4 | -1.0 | -0.6 | -0.0 | -0.7 | 0.2 |
| Saxagliptin, 5 mg + Insulin | -0.5 | -0.5 | -0.5 | -0.0 | 0.3 | -1.0 | -0.5 | 0.0 | -1.0 | 0.0 | 0.2 | -0.3 |
(NCT00757588)
Timeframe: Baseline to Weeks 2, 4, 6, 8, 12, 16, 20, 24, 28, 36, 44, and 52
| Intervention | mm Hg (Number) | |||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Systolic blood pressure (Week 2) (n=294, 147) | Systolic blood pressure (Week 4) (n=293, 144) | Systolic blood pressure (Week 6) (n=280, 141) | Systolic blood pressure (Week 8) (n=290, 142) | Systolic blood pressure (Week 12) (n=286, 144) | Systolic blood pressure (Week 16) (n=278, 139) | Systolic blood pressure (Week 20) (n=276, 137) | Systolic blood pressure (Week 24) (n=273, 134) | Systolic blood pressure (Week 28) (n=264, 132) | Systolic blood pressure (Week 36) (n=261, 129) | Systolic blood pressure (Week 44) (n=250, 125) | Systolic blood pressure (Week 52) (n=246, 125) | Diastolic blood pressure (Week 2) (n=294, 147) | Diastolic blood pressure (Week 4) (n=293, 144) | Diastolic blood pressure (Week 6) (n=280, 141) | Diastolic blood pressure (Week 8) (n=290, 142) | Diastolic blood pressure (Week 12) (n=286, 144) | Diastolic blood pressure (Week 16) (n=278, 139) | Diastolic blood pressure (Week 20) (n=276, 137) | Diastolic blood pressure (Week 24) (n=273, 134) | Diastolic blood pressure (Week 28) (n=264, 132) | Diastolic blood pressure (Week 36) (n=261, 129) | Diastolic blood pressure (Week 44) (n=250, 125) | Diastolic blood pressure (Week 52) (n=246, 125) | |
| Placebo + Insulin | 2.3 | 0.0 | 1.0 | 2.4 | 2.2 | 1.1 | 1.3 | -0.1 | 1.8 | 3.6 | 2.6 | 1.0 | 1.4 | 1.8 | 0.3 | 2.1 | 1.0 | 1.3 | 1.1 | 0.5 | 0.2 | 0.2 | 0.4 | 0.1 |
| Saxagliptin, 5 mg + Insulin | -1.0 | -1.2 | -0.8 | -0.8 | -1.7 | -1.2 | -0.6 | -1.5 | -1.4 | -0.7 | -0.6 | 0.0 | 0.1 | 0.0 | 0.0 | -0.5 | -0.8 | -1.1 | -0.7 | -1.7 | -1.6 | -1.2 | -0.3 | -0.5 |
An AE is any new untoward medical occurrence or worsening of a preexisting medical condition that does not necessarily have a causal relationship with this treatment. An SAE is any untoward medical event that at any dose: results in death, persistent or significant disability/incapacity, or drug dependency or abuse; is life-threatening, an important medical event, or a congenital anomaly/birth defect; requires inpatient hospitalization; or prolongs existing hospitalization. Treatment-related=possibly, probably, or certainly related to and of unknown relationship to study treatment. (NCT00757588)
Timeframe: Baseline to Week 52, continuously
| Intervention | Participants (Number) | ||||||
|---|---|---|---|---|---|---|---|
| At least 1 AE | At least 1 treatment-related AE | Deaths | At least 1 SAE | At least 1 treatment-related SAE | Discontinuations due to SAEs | Discontinuations due to AEs | |
| Placebo + Insulin | 108 | 34 | 0 | 13 | 0 | 0 | 3 |
| Saxagliptin, 5 mg + Insulin | 202 | 56 | 2 | 25 | 3 | 4 | 9 |
"Marked abnormality=a laboratory value lying outside the predefined criteria and more extreme (farther from the limit)on-treatment than at baseline. ULN=upper limit of normal; LLN=lower limit of normal; prx=pre-RX=pretreatment.~Criteria 1: if prx=0 use >=2, if prx=0.5 or 1 use >=3, if prx=2 use 4." (NCT00757588)
Timeframe: Baseline and during and up to 14 days after last dose of study drug (in Week 52)
| Intervention | Participants (Number) | |||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Hemoglobin <8 g/dL (n=300; 150) | Hematocrit <0.75*prx (n=300; 150) | Platelets <50*10^9 c/L (n=297; 145) | Platelets >1.5*ULN (n=297; 145) | Leukocytes <2*1000 c/uL (n=300; 150) | Neutrophils <1*1000 c/uL (n=296; 150) | Eosinophils >0.9*1000 c/uL (n=296; 150) | Lymphocytes <=0.75*1000 c/uL (n=296; 150) | Alkaline phosphatase >3*prx & >ULN (n=302; 150) | Alkaline phosphatase >1.5 ULN (n=302; 150) | Aspartate aminotransferase >3* ULN (n=298; 148) | Aspartate aminotransferase>5* ULN (n=298; 148) | Aspartate aminotransferase >10*ULN (n=298; 148) | Aspartate aminotransferase >20*ULN (n=298; 148) | Alanine transaminase >3*ULN (n=300; 148) | Alanine transaminase >5*ULN (n=300; 148) | Alanine transaminase >10*ULN (n=300; 148) | Alanine transaminase >20*ULN (n=300; 148) | Bilirubin, total >2 mg/dL (n=301; 150) | Bilirubin, total >1.5*ULN (n=301; 150) | Bilirubin, total >2*ULN (n=301; 150) | Blood urea nitrogen >2*prx & >ULN (n=302; 150) | Creatinine >2.5 mg/dL (n=303; 150) | Glucose, serum fasting <50 mg/dL (n=0; 0) | Glucose, serum fasting >500 mg/dL (n=0; 0) | Glucose, serum unspecified <50 mg/dL (n=0; 0) | Glucose, serum unspecified >500 mg/dL (n=0; 0) | Glucose, plasma fasting <50 mg/dL (n=301;150) | Glucose, plasma fasting >500 mg/dL (n=301;150) | Glucose, plasma unspecified <50 mg/dL (n=272; 133) | Glucose, plasma unspecified >500 mg/d (n=272; 133) | Sodium, serum <0.9*prx & <=130 mEq/L (n=302; 150) | Sodium, serum >1.1*prx & >=150 mEq/L (n=302; 150) | Potassium, serum <0.8 prx &<=3.2 mEq/L(n=300; 148) | Potassium, serum >1.2*prx&>= 6.0 mEq/L(n=300; 148) | Chloride, serum <90 mEq/L (n=302; 150) | Chloride, serum >120 mEq/L (n=302; 150) | Albumin <0.9*LLN; if prx| Creatine kinase >5*ULN (n=301, 148) | Uric acid >1.5*ULN; if prx >ULN, >2 (n=0,0) | Protein urine (see criteria 1) (n=297,146) | Blood urine (see criteria 1) (n=297; 146) | Red blood cells urine (see criteria 1) (n=53; 31) | White blood cells urine (see criteria 1)(n=115;53) | | |
| Placebo + Insulin | 0 | 2 | 0 | 0 | 1 | 0 | 7 | 2 | 1 | 5 | 0 | 0 | 0 | 0 | 3 | 0 | 0 | 0 | 0 | 1 | 0 | 7 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 1 | 0 | 0 | 1 | 8 | 0 | 0 | 0 | 2 | 0 | 3 | 2 | 3 | 10 |
| Saxagliptin, 5 mg + Insulin | 2 | 2 | 0 | 0 | 0 | 1 | 9 | 3 | 2 | 10 | 2 | 1 | 0 | 0 | 5 | 1 | 0 | 0 | 0 | 0 | 0 | 5 | 0 | 0 | 0 | 0 | 0 | 5 | 0 | 5 | 1 | 1 | 0 | 3 | 8 | 1 | 0 | 1 | 6 | 0 | 8 | 14 | 8 | 35 |
Confirmed hypoglycemia=fingerstick glucose measurement of ≤50 mg/dL with associated symptoms/ (NCT00757588)
Timeframe: Baseline to Week 52
| Intervention | Percentage of Participants (Number) | |
|---|---|---|
| Reported | Confirmed | |
| Placebo + Insulin | 24.5 | 6.6 |
| Saxagliptin, 5 mg + Insulin | 19.4 | 7.6 |
Absolute lymphocyte count=value*10^3 c/uL (NCT00757588)
Timeframe: Baseline and Weeks 24 and 52
| Intervention | Participants (Number) | |||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Baseline <= 0.75; Week 24 <= 0.75 | Baseline <= 0.75; Week 24 >0.75- <= 5.00 | Baseline <= 0.75; Week 24 >5.00 | Baseline >0.75- <= 5.00; Week 24 <= 0.75 | Baseline >0.75- <= 5.00; Week 24 >0.75- <= 5.00 | Baseline >0.75- <= 5.00; Week 24 >5.00 | Baseline >5.00; Week 24 <= 0.75 | Baseline >5.00; Week 24 >0.75- <= 5.00 | Baseline >5.00; Week 24 >5.00 | Baseline <= 0.75; Week 52 <= 0.75 | Baseline <= 0.75; Week 52 >0.75- <= 5.00 | Baseline <= 0.75; Week 52 >5.00 | Baseline >0.75- <= 5.00; Week 52 <= 0.75 | Baseline >0.75- <= 5.00; Week 52 >0.75- <= 5.00 | Baseline >0.75- <= 5.00; Week 52 >5.00 | Baseline >5.00; Week 52 <= 0.75 | Baseline >5.00; Week 52 >0.75- <= 5.00 | Baseline >5.00; Week 52 >5.00 | |
| Placebo + Insulin | 0 | 2 | 0 | 0 | 148 | 0 | 0 | 0 | 0 | 0 | 2 | 0 | 0 | 147 | 1 | 0 | 0 | 0 |
| Saxagliptin, 5 mg + Insulin | 0 | 0 | 0 | 1 | 293 | 1 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 295 | 0 | 0 | 0 | 1 |
Platelet count=value*10^9 c/L (NCT00757588)
Timeframe: Baseline and Weeks 24 and 52
| Intervention | Participants (Number) | |||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Baseline <= 100; Week 24 <= 100 | Baseline <= 100; Week 24 >100 - <= 600 | Baseline <= 100; Week 24 >600 | Baseline >100 - <= 600; Week 24 <= 100 | Baseline >100 - <= 600; Week 24 >100 - <= 600 | Baseline >100 - <= 600; Week 24 >600 | Baseline >600; Week 24 <= 100 | Baseline >600; Week 24 >100 - <= 600 | Baseline >600; Week 24 >600 | Baseline <= 100; Week 52 <= 100 | Baseline <= 100; Week 52 >100 - <= 600 | Baseline <= 100; Week 52 >600 | Baseline >100 - <= 600; Week 52 <= 100 | Baseline >100 - <= 600; Week 52 >100 - <= 600 | Baseline >100 - <= 600; Week 52 >600 | Baseline >600; Week 52 <= 100 | Baseline >600; Week 52 >100 - <= 600 | Baseline >600; Week 52 >600 | |
| Placebo + Insulin | 0 | 0 | 0 | 1 | 143 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 144 | 0 | 0 | 0 | 0 |
| Saxagliptin, 5 mg + Insulin | 0 | 0 | 0 | 1 | 296 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2 | 295 | 0 | 0 | 0 | 0 |
Percentage of participants achieving A1C < 7%, the American Diabetes Association's defined goal for glycemia, at each dose of saxagliptin plus metformin versus metformin alone at Week 24. (NCT00327015)
Timeframe: Week 24
| Intervention | Percentage of participants (Number) |
|---|---|
| Saxagliptin 5 mg + Metformin | 60.3 |
| Saxagliptin 10 mg + Metformin | 59.7 |
| Metformin | 41.1 |
Percentage of participants achieving A1C < 7%, the American Diabetes Association's defined goal for glycemia, at each dose of saxagliptin plus metformin versus saxagliptin alone at Week 24. (NCT00327015)
Timeframe: Week 24
| Intervention | Percentage of participants (Number) |
|---|---|
| Saxagliptin 5 mg + Metformin | 60.3 |
| Saxagliptin 10 mg + Metformin | 59.7 |
| Saxagliptin 10 mg | 32.2 |
Percentage of participants achieving A1C ≤6.5%, at each dose of saxagliptin plus metformin versus metformin alone at Week 24. (NCT00327015)
Timeframe: Week 24
| Intervention | Percentage of participants (Number) |
|---|---|
| Saxagliptin 5 mg + Metformin | 45.3 |
| Saxagliptin 10 mg + Metformin | 40.6 |
| Metformin | 29.0 |
Percentage of participants achieving A1C ≤6.5%, at each dose of saxagliptin plus metformin versus saxagliptin alone at Week 24. (NCT00327015)
Timeframe: Week 24
| Intervention | Percentage of Participants (Number) |
|---|---|
| Saxagliptin 5 mg + Metformin | 45.3 |
| Saxagliptin 10 mg + Metformin | 40.6 |
| Saxagliptin 10 mg | 20.3 |
Percentage of participants requiring rescue for failing to achieve pre-specified glycemic targets or discontinuing for lack of efficacy within the 24-week treatment period at each dose of saxagliptin plus metformin versus metformin alone. (NCT00327015)
Timeframe: Week 24
| Intervention | Percentage of participants (Number) |
|---|---|
| Saxagliptin 5 mg + Metformin | 7.5 |
| Saxagliptin 10 mg + Metformin | 5.9 |
| Metformin | 10.1 |
Percentage of participants requiring rescue for failing to achieve pre-specified glycemic targets or discontinuing for lack of efficacy within the 24-week treatment period at each dose of saxagliptin plus metformin versus saxagliptin alone. (NCT00327015)
Timeframe: Week 24
| Intervention | Percentage of participants (Number) |
|---|---|
| Saxagliptin 5 mg + Metformin | 7.5 |
| Saxagliptin 10 mg + Metformin | 5.9 |
| Saxagliptin 10 mg | 21.2 |
Mean change from baseline in A1C at Week 24, adjusted for baseline value. (NCT00327015)
Timeframe: Baseline, Week 24
| Intervention | percent (Mean) | ||
|---|---|---|---|
| Baseline Mean | Week 24 Mean | Adjusted Mean Change from Baseline | |
| Metformin | 9.43 | 7.48 | -1.99 |
| Saxagliptin 10 mg + Metformin | 9.53 | 7.02 | -2.49 |
| Saxagliptin 5 mg + Metformin | 9.41 | 6.93 | -2.53 |
Mean change from baseline in FPG at Week 24, adjusted for baseline value. (NCT00327015)
Timeframe: Baseline, Week 24
| Intervention | mg/dL (Mean) | ||
|---|---|---|---|
| Baseline Mean | Week 24 Mean | Adjusted Mean Change from Baseline | |
| Metformin | 199.1 | 152.7 | -47.3 |
| Saxagliptin 10 mg + Metformin | 204.3 | 140.1 | -62.2 |
| Saxagliptin 5 mg + Metformin | 198.9 | 140.2 | -59.8 |
Mean change from baseline in FPG at Week 24, adjusted for baseline value. (NCT00327015)
Timeframe: Baseline, Week 24
| Intervention | mg/dL (Mean) | ||
|---|---|---|---|
| Baseline Mean | Week 24 Mean | Adjusted Mean Change from Baseline | |
| Saxagliptin 10 mg | 200.9 | 169.9 | -30.9 |
| Saxagliptin 10 mg + Metformin | 204.3 | 140.1 | -62.2 |
| Saxagliptin 5 mg + Metformin | 198.9 | 140.2 | -59.8 |
Mean change from baseline in A1C at Week 24, adjusted for baseline value. (NCT00327015)
Timeframe: Baseline, Week 24
| Intervention | percent (Mean) | ||
|---|---|---|---|
| Baseline Mean | Week 24 Mean | Adjusted Mean Change from Baseline | |
| Saxagliptin 10 mg | 9.61 | 7.86 | -1.69 |
| Saxagliptin 10 mg + Metformin | 9.53 | 7.02 | -2.49 |
| Saxagliptin 5 mg + Metformin | 9.41 | 6.93 | -2.53 |
Mean change from baseline for 0 to 180 minutes PPG AUC at Week 24, adjsuted for baseline value. (NCT00327015)
Timeframe: Baseline, Week 24
| Intervention | mg*min/dL (Mean) | ||
|---|---|---|---|
| Baseline Mean | Week 24 Mean | Adjusted Mean Change from Baseline | |
| Metformin | 57937 | 42428 | -15005 |
| Saxagliptin 10 mg + Metformin | 57219 | 35790 | -21336 |
| Saxagliptin 5 mg + Metformin | 55531 | 35324 | -21080 |
Mean change from baseline for 0 to 180 minutes PPG AUC at Week 24, adjusted for baseline value. (NCT00327015)
Timeframe: Baseline, Week 24
| Intervention | mg*min/dL (Mean) | ||
|---|---|---|---|
| Baseline Mean | Week 24 Mean | Adjusted Mean Change from Baseline | |
| Saxagliptin 10 mg | 57584 | 41229 | -16054 |
| Saxagliptin 10 mg + Metformin | 57219 | 35790 | -21336 |
| Saxagliptin 5 mg + Metformin | 55531 | 35324 | -21080 |
Change from baseline at Week 104 is defined as Week 104 minus Week 0. (NCT00094770)
Timeframe: Baseline and Week 104
| Intervention | Kilograms (Least Squares Mean) |
|---|---|
| Sitagliptin 100 mg | -1.6 |
| Glipizide | 0.7 |
Change from baseline at Week 52 is defined as Week 52 minus Week 0. (NCT00094770)
Timeframe: Baseline and Week 52
| Intervention | Kilograms (Least Squares Mean) |
|---|---|
| Sitagliptin 100 mg | -1.5 |
| Glipizide | 1.1 |
HbA1c is measured as percent. Thus, this change from baseline reflects the Week 104 HbA1c percent minus the Week 0 HbA1c percent. (NCT00094770)
Timeframe: Baseline and Week 104
| Intervention | Percent (Least Squares Mean) |
|---|---|
| Sitagliptin 100 mg | -0.54 |
| Glipizide | -0.51 |
HbA1c is measured as percent. Thus, this change from baseline reflects the Week 52 HbA1c percent minus the Week 0 HbA1c percent. (NCT00094770)
Timeframe: Baseline and Week 52
| Intervention | Percent (Least Squares Mean) |
|---|---|
| Sitagliptin 100 mg | -0.67 |
| Glipizide | -0.67 |
Participants with drug-related (as assessed by an investigator who is a qualified physician according to his/her best clinical judgment) LAEs. (NCT00094770)
Timeframe: Baseline to Week 104
| Intervention | Participants (Number) |
|---|---|
| Sitagliptin 100 mg | 18 |
| Glipizide | 21 |
Number of participants who reported 1 or more episodes of the adverse experience of hypoglycemia. (NCT00094770)
Timeframe: Baseline to Week 104
| Intervention | Participants (Number) | ||
|---|---|---|---|
| Participants with one or more Hypoglycemic AEs | Total number of Hypoglycemic episodes | Participants with no Hypoglycemic AEs | |
| Glipizide | 199 | 805 | 385 |
| Sitagliptin 100 mg | 31 | 57 | 557 |
Number of participants who reported 1 or more episodes of the adverse experience (AEs) of hypoglycemia. (NCT00094770)
Timeframe: Baseline to Week 52
| Intervention | Participants (Number) | ||
|---|---|---|---|
| Participants with one or more Hypoglycemic AEs | Total number of Hypoglycemic episodes | Participants with no Hypoglycemic AEs | |
| Glipizide | 187 | 657 | 397 |
| Sitagliptin 100 mg | 29 | 50 | 559 |
An adverse experience (AE) is defined as any unfavorable and unintended change in the structure, function, or chemistry of the body temporally associated with the use of the SPONSOR'S product, whether or not considered related to the use of the product. (NCT00094770)
Timeframe: Baseline to Week 104
| Intervention | Participants (Number) | |
|---|---|---|
| With CAES | Without CAES | |
| Glipizide | 480 | 104 |
| Sitagliptin 100 mg | 452 | 136 |
Participants with drug-related (as assessed by an investigator who is a qualified physician according to his/her best clinical judgment) CAEs. (NCT00094770)
Timeframe: Baseline to Week 104
| Intervention | Participants (Number) | |
|---|---|---|
| With drug related CAEs | Without drug related CAEs | |
| Glipizide | 193 | 391 |
| Sitagliptin 100 mg | 97 | 491 |
A laboratory adverse experience (LAE) is defined as any unfavorable and unintended change in the chemistry of the body temporally associated with the use of the SPONSOR'S product, whether or not considered related to the use of the product. (NCT00094770)
Timeframe: Baseline to Week 104
| Intervention | Participants (Number) | |
|---|---|---|
| With LAEs | Without LAEs | |
| Glipizide | 74 | 510 |
| Sitagliptin 100 mg | 85 | 503 |
Serious CAEs are any AEs occurring at any dose that; Results in death; or Is life threatening; or Results in a persistent or significant disability/incapacity; or Results in or prolongs an existing inpatient hospitalization; or Is a congenital anomaly/birth defect; or Is a cancer; or Is an overdose. (NCT00094770)
Timeframe: Baseline to Week 104
| Intervention | Participants (Number) | |
|---|---|---|
| With serious CAEs | Without serious CAEs | |
| Glipizide | 73 | 511 |
| Sitagliptin 100 mg | 64 | 524 |
Serious LAEs are any LAEs occurring at any dose that: results in death; or is life threatening; or results in a persistent or significant disability/incapacity; or results in or prolongs an existing inpatient hospitalization; or is a congenital anomaly/birth defect; or is a cancer; or is an overdose. (NCT00094770)
Timeframe: Baseline to Week 104
| Intervention | Participants (Number) | |
|---|---|---|
| With serious LAEs | Without serious LAEs | |
| Glipizide | 0 | 584 |
| Sitagliptin 100 mg | 0 | 588 |
6 reviews available for glipizide and Fasting Hypoglycemia
| Article | Year |
|---|---|
Systematic review and meta-analysis of head-to-head trials comparing sulfonylureas and low hypoglycaemic risk antidiabetic drugs.
Topics: Adolescent; Adult; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Dipeptidyl-Peptida | 2022 |
The Patient Faints in the Waiting Area with a Suspected Hypoglycemic Event.
Topics: Aged; Female; Glipizide; Humans; Hypoglycemia; Hypoglycemic Agents; Sulfonylurea Compounds | 2023 |
Current understanding of feline diabetes: part 2, treatment.
Topics: Animals; Blood Glucose; Body Weight; Cat Diseases; Cats; Diabetes Complications; Diabetes Mellitus; | 2000 |
Hypoglycemia of obscure cause.
Topics: C-Peptide; Diagnosis, Differential; Fasting; Glipizide; Humans; Hypoglycemia; Insulin; Male; Medicat | 1992 |
Glipizide: an oral hypoglycemic drug.
Topics: Administration, Oral; Blood Glucose; Glipizide; Humans; Hypoglycemia; Hypoglycemic Agents; Sulfonylu | 1989 |
Sulfonylureas in the treatment of diabetes mellitus--1985.
Topics: Blood Glucose; Body Weight; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Drug Therapy, Comb | 1985 |
14 trials available for glipizide and Fasting Hypoglycemia
| Article | Year |
|---|---|
Alogliptin versus glipizide monotherapy in elderly type 2 diabetes mellitus patients with mild hyperglycaemia: a prospective, double-blind, randomized, 1-year study.
Topics: Aged; Aged, 80 and over; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitor | 2013 |
Saxagliptin vs. glipizide as add-on therapy in patients with type 2 diabetes mellitus inadequately controlled on metformin alone: long-term (52-week) extension of a 52-week randomised controlled trial.
Topics: Adamantane; Adult; Aged; Aged, 80 and over; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptides; Di | 2013 |
Saxagliptin versus glipizide as add-on therapy to metformin: assessment of hypoglycemia.
Topics: Adamantane; Adult; Aged; Aged, 80 and over; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptid | 2014 |
Durability of glycaemic efficacy over 2 years with dapagliflozin versus glipizide as add-on therapies in patients whose type 2 diabetes mellitus is inadequately controlled with metformin.
Topics: Benzhydryl Compounds; Blood Glucose; Blood Pressure; Body Weight; Diabetes Mellitus, Type 2; Dose-Re | 2014 |
Durability of glycaemic efficacy over 2 years with dapagliflozin versus glipizide as add-on therapies in patients whose type 2 diabetes mellitus is inadequately controlled with metformin.
Topics: Benzhydryl Compounds; Blood Glucose; Blood Pressure; Body Weight; Diabetes Mellitus, Type 2; Dose-Re | 2014 |
Durability of glycaemic efficacy over 2 years with dapagliflozin versus glipizide as add-on therapies in patients whose type 2 diabetes mellitus is inadequately controlled with metformin.
Topics: Benzhydryl Compounds; Blood Glucose; Blood Pressure; Body Weight; Diabetes Mellitus, Type 2; Dose-Re | 2014 |
Durability of glycaemic efficacy over 2 years with dapagliflozin versus glipizide as add-on therapies in patients whose type 2 diabetes mellitus is inadequately controlled with metformin.
Topics: Benzhydryl Compounds; Blood Glucose; Blood Pressure; Body Weight; Diabetes Mellitus, Type 2; Dose-Re | 2014 |
Durability of the efficacy and safety of alogliptin compared with glipizide in type 2 diabetes mellitus: a 2-year study.
Topics: Adult; Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase | 2014 |
Saxagliptin efficacy and safety in patients with type 2 diabetes mellitus stratified by cardiovascular disease history and cardiovascular risk factors: analysis of 3 clinical trials.
Topics: Adamantane; Adult; Blood Glucose; Body Weight; Cardiovascular Diseases; Diabetes Mellitus, Type 2; D | 2014 |
Saxagliptin efficacy and safety in patients with type 2 diabetes mellitus stratified by cardiovascular disease history and cardiovascular risk factors: analysis of 3 clinical trials.
Topics: Adamantane; Adult; Blood Glucose; Body Weight; Cardiovascular Diseases; Diabetes Mellitus, Type 2; D | 2014 |
Saxagliptin efficacy and safety in patients with type 2 diabetes mellitus stratified by cardiovascular disease history and cardiovascular risk factors: analysis of 3 clinical trials.
Topics: Adamantane; Adult; Blood Glucose; Body Weight; Cardiovascular Diseases; Diabetes Mellitus, Type 2; D | 2014 |
Saxagliptin efficacy and safety in patients with type 2 diabetes mellitus stratified by cardiovascular disease history and cardiovascular risk factors: analysis of 3 clinical trials.
Topics: Adamantane; Adult; Blood Glucose; Body Weight; Cardiovascular Diseases; Diabetes Mellitus, Type 2; D | 2014 |
Saxagliptin efficacy and safety in patients with type 2 diabetes mellitus stratified by cardiovascular disease history and cardiovascular risk factors: analysis of 3 clinical trials.
Topics: Adamantane; Adult; Blood Glucose; Body Weight; Cardiovascular Diseases; Diabetes Mellitus, Type 2; D | 2014 |
Saxagliptin efficacy and safety in patients with type 2 diabetes mellitus stratified by cardiovascular disease history and cardiovascular risk factors: analysis of 3 clinical trials.
Topics: Adamantane; Adult; Blood Glucose; Body Weight; Cardiovascular Diseases; Diabetes Mellitus, Type 2; D | 2014 |
Saxagliptin efficacy and safety in patients with type 2 diabetes mellitus stratified by cardiovascular disease history and cardiovascular risk factors: analysis of 3 clinical trials.
Topics: Adamantane; Adult; Blood Glucose; Body Weight; Cardiovascular Diseases; Diabetes Mellitus, Type 2; D | 2014 |
Saxagliptin efficacy and safety in patients with type 2 diabetes mellitus stratified by cardiovascular disease history and cardiovascular risk factors: analysis of 3 clinical trials.
Topics: Adamantane; Adult; Blood Glucose; Body Weight; Cardiovascular Diseases; Diabetes Mellitus, Type 2; D | 2014 |
Saxagliptin efficacy and safety in patients with type 2 diabetes mellitus stratified by cardiovascular disease history and cardiovascular risk factors: analysis of 3 clinical trials.
Topics: Adamantane; Adult; Blood Glucose; Body Weight; Cardiovascular Diseases; Diabetes Mellitus, Type 2; D | 2014 |
Long-term glycaemic response and tolerability of dapagliflozin versus a sulphonylurea as add-on therapy to metformin in patients with type 2 diabetes: 4-year data.
Topics: Aged; Benzhydryl Compounds; Blood Glucose; Blood Pressure; Body Weight; Diabetes Mellitus, Type 2; D | 2015 |
Saxagliptin is non-inferior to glipizide in patients with type 2 diabetes mellitus inadequately controlled on metformin alone: a 52-week randomised controlled trial.
Topics: Adamantane; Aged; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhi | 2010 |
Sitagliptin more effectively achieves a composite endpoint for A1C reduction, lack of hypoglycemia and no body weight gain compared with glipizide.
Topics: Aged; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Double-Blind Method; Female; Gl | 2011 |
Beta-cell insulin secretory response to oral hypoglycemic agents is blunted in humans in vivo during moderate hypoglycemia.
Topics: Administration, Oral; Adult; Carbamates; Cross-Over Studies; Double-Blind Method; Female; Glipizide; | 2004 |
Effect on glycemic control of the addition of 2.5 mg glipizide GITS to metformin in patients with T2DM.
Topics: Blood Glucose; Chemistry, Pharmaceutical; Delayed-Action Preparations; Diabetes Mellitus, Type 2; Do | 2005 |
Glipizide-GITS does not increase the hypoglycemic effect of mild exercise during fasting in NIDDM.
Topics: Adult; Aged; Blood Glucose; C-Peptide; Diabetes Mellitus; Diabetes Mellitus, Type 2; Double-Blind Me | 1997 |
A prospective trial of risk factors for sulfonylurea-induced hypoglycemia in type 2 diabetes mellitus.
Topics: Age Factors; Aged; Analysis of Variance; Blood Chemical Analysis; Blood Glucose; Diabetes Mellitus, | 1998 |
Conversion from low-dose insulin therapy to glipizide in patients with non-insulin-dependent diabetes mellitus.
Topics: Adult; Blood Glucose; Body Weight; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Drug Adminis | 1987 |
56 other studies available for glipizide and Fasting Hypoglycemia
| Article | Year |
|---|---|
Comparative safety of sulfonylureas among U.S. nursing home residents.
Topics: Aged; Female; Glipizide; Glyburide; Humans; Hypoglycemia; Male; Medicare; Myocardial Infarction; Nur | 2023 |
Comparative safety of sulfonylureas among U.S. nursing home residents.
Topics: Aged; Female; Glipizide; Glyburide; Humans; Hypoglycemia; Male; Medicare; Myocardial Infarction; Nur | 2023 |
Comparative safety of sulfonylureas among U.S. nursing home residents.
Topics: Aged; Female; Glipizide; Glyburide; Humans; Hypoglycemia; Male; Medicare; Myocardial Infarction; Nur | 2023 |
Comparative safety of sulfonylureas among U.S. nursing home residents.
Topics: Aged; Female; Glipizide; Glyburide; Humans; Hypoglycemia; Male; Medicare; Myocardial Infarction; Nur | 2023 |
The presence of two reduced function variants in CYP2C9 influences the acute response to glipizide.
Topics: Adult; Blood Glucose; Cytochrome P-450 CYP2C9; Female; Glipizide; Humans; Hypoglycemia; Hypoglycemic | 2020 |
Angiotensin-Converting Enzyme Inhibitors Used Concomitantly with Insulin Secretagogues and the Risk of Serious Hypoglycemia.
Topics: Administrative Claims, Healthcare; Aged; Aged, 80 and over; Angiotensin-Converting Enzyme Inhibitors | 2022 |
Sentinel Modular Program for Propensity Score-Matched Cohort Analyses: Application to Glyburide, Glipizide, and Serious Hypoglycemia.
Topics: Adult; Aged; Cohort Studies; Diabetes Mellitus, Type 2; Emergency Service, Hospital; Female; Glipizi | 2017 |
Pharmacologic Differences of Sulfonylureas and the Risk of Adverse Cardiovascular and Hypoglycemic Events.
Topics: Aged; Aged, 80 and over; Body Mass Index; Cardiovascular Diseases; Cohort Studies; Diabetes Mellitus | 2017 |
Risk of Hypoglycemia Following Hospital Discharge in Patients With Diabetes and Acute Kidney Injury.
Topics: Acute Kidney Injury; Adult; Aged; Blood Glucose; Diabetes Mellitus; Diabetic Nephropathies; Female; | 2018 |
Comparative Safety of Sulfonylureas and the Risk of Sudden Cardiac Arrest and Ventricular Arrhythmia.
Topics: Aged; Arrhythmias, Cardiac; Cause of Death; Death, Sudden, Cardiac; Diabetic Angiopathies; Female; G | 2018 |
Case 3: Acute Hypotonia, Hypothermia, and Altered Mental Status in a 10-month-old Girl.
Topics: Acute Disease; Consciousness Disorders; Female; Glipizide; Humans; Hypoglycemia; Hypoglycemic Agents | 2018 |
Continuous octreotide infusion for sulfonylurea-induced hypoglycemia in a toddler.
Topics: Glipizide; Humans; Hypoglycemia; Infant; Infusions, Intravenous; Male; Octreotide; Sulfonylurea Comp | 2013 |
Hypoglycemia, its implications in clinical practice, and possible ways to prevent it.
Topics: Adamantane; Diabetes Mellitus, Type 2; Dipeptides; Female; Glipizide; Humans; Hypoglycemia; Male; Me | 2014 |
Pharmacoepidemiologic and in vitro evaluation of potential drug-drug interactions of sulfonylureas with fibrates and statins.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Area Under Curve; Case-Control Studies; Cytochrome P-450 | 2014 |
Coadministration of co-trimoxazole with sulfonylureas: hypoglycemia events and pattern of use.
Topics: Aged; Aged, 80 and over; Anti-Infective Agents; Cohort Studies; Diabetes Mellitus; Drug Interactions | 2015 |
Hypoglycemia after antimicrobial drug prescription for older patients using sulfonylureas.
Topics: Aged; Aged, 80 and over; Anti-Infective Agents; Ciprofloxacin; Clarithromycin; Drug Interactions; Dr | 2014 |
Severe hypoglycemia in users of sulfonylurea antidiabetic agents and antihyperlipidemics.
Topics: Aged; Algorithms; Cohort Studies; Drug Interactions; Female; Fenofibrate; Glipizide; Glyburide; Huma | 2016 |
Association between use of warfarin with common sulfonylureas and serious hypoglycemic events: retrospective cohort analysis.
Topics: Age Factors; Aged; Aged, 80 and over; Anticoagulants; Diabetes Mellitus, Type 2; Emergency Service, | 2015 |
Biomedical Informatics Approaches to Identifying Drug-Drug Interactions: Application to Insulin Secretagogues.
Topics: Area Under Curve; Carbamates; Cyclohexanes; Databases, Factual; Diabetes Mellitus, Type 2; Drug Inte | 2017 |
Extended-release glipizide overdose presenting with delayed hypoglycemia and treated with subcutaneous octreotide.
Topics: Child; Drug Overdose; Female; Gastrointestinal Agents; Glipizide; Glucose; Humans; Hyperinsulinism; | 2009 |
Hypoglycemia associated with the use of levofloxacin.
Topics: Anti-Bacterial Agents; Community-Acquired Infections; Diabetes Mellitus, Type 2; Drug Interactions; | 2009 |
Quinolone-induced hypoglycemia: a life-threatening but potentially reversible side effect.
Topics: Aged; Anti-Infective Agents; Ciprofloxacin; Diabetes Mellitus, Type 2; Female; Gastrointestinal Agen | 2010 |
Pediatric glipizide ingestion, onset of hypoglycemia, and octreotide.
Topics: Gastrointestinal Agents; Glipizide; Humans; Hypoglycemia; Hypoglycemic Agents; Octreotide | 2009 |
Anti-infectives and the risk of severe hypoglycemia in users of glipizide or glyburide.
Topics: Adolescent; Adult; Aged; Anti-Infective Agents; Antifungal Agents; Aryl Hydrocarbon Hydroxylases; Bl | 2010 |
Quantitative insulin and C-peptide levels among ED patients with sulfonylurea-induced hypoglycemia-a prospective case series.
Topics: Aged; Aged, 80 and over; C-Peptide; Cross-Sectional Studies; Drug Overdose; Female; Glipizide; Glybu | 2010 |
Hypoglycemia after accidental pediatric sulfonylurea ingestions.
Topics: Accidents, Home; Arizona; Blood Glucose; Child, Preschool; Emergency Service, Hospital; Glipizide; G | 2011 |
Glycemic control and hypoglycemia in Veterans Health Administration patients converted from glyburide to glipizide.
Topics: Aged; Blood Glucose; Creatinine; Diabetes Mellitus; Female; Glipizide; Glyburide; Glycated Hemoglobi | 2011 |
[Munchausen syndrome in an extreme form of factitious disorder].
Topics: Adult; Colectomy; Colon; Female; Gangrene; Glipizide; Humans; Hypoglycemia; Hypoglycemic Agents; Mun | 2011 |
Hypoglycemia in hospitalized patients treated with sulfonylureas.
Topics: Academic Medical Centers; Age Factors; Aged; Blood Glucose; Case-Control Studies; Drug Therapy, Comb | 2012 |
Lower risk of hypoglycemia with sitagliptin compared to glipizide when either is added to metformin therapy: a pre-specified analysis adjusting for the most recently measured HbA(1c) value.
Topics: Adult; Aged; Aged, 80 and over; Calibration; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Th | 2012 |
Severe hypoglycemia from clarithromycin-sulfonylurea drug interaction.
Topics: Aged; Aged, 80 and over; Anti-Bacterial Agents; Clarithromycin; Drug Interactions; Glipizide; Glybur | 2002 |
Use of octreotide to treat prolonged sulfonylurea-induced hypoglycemia in a patient with chronic renal failure.
Topics: Adult; C-Peptide; Diabetes Mellitus, Type 2; Gastrointestinal Agents; Glipizide; Humans; Hypoglycemi | 2003 |
Prolonged hypoglycaemia secondary to extended-release form glipizide.
Topics: Delayed-Action Preparations; Glipizide; Humans; Hypoglycemia; Hypoglycemic Agents | 2004 |
Glipizide matrix transdermal systems for diabetes mellitus: preparation, in vitro and preclinical studies.
Topics: Acrylic Resins; Administration, Cutaneous; Animals; Cellulose; Diabetes Mellitus; Drug Delivery Syst | 2006 |
How a series of errors led to recurrent hypoglycemia.
Topics: Communication; Glipizide; Humans; Hypoglycemia; Hypoglycemic Agents; Male; Medication Errors; Middle | 2006 |
Toxicology case of the month: oral hypoglycaemic overdose.
Topics: Adolescent; Drug Overdose; Emergency Service, Hospital; Female; Glipizide; Humans; Hypoglycemia; Hyp | 2006 |
Case files of the Medical Toxicology Fellowship Training Program at the Children's Hospital of Philadelphia: a pediatric exploratory sulfonylurea ingestion.
Topics: Administration, Oral; Antidotes; Blood Glucose; Child, Preschool; Glipizide; Glucose; Humans; Hypogl | 2006 |
Hypoglycaemia in patients with type 2 diabetes treated with a combination of metformin and sulphonylurea therapy in France.
Topics: Cross-Sectional Studies; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; France; Glipi | 2008 |
Glipizide: experimental study and comparison with other sulfonylureas.
Topics: Animals; Blood Glucose; Dogs; Dose-Response Relationship, Drug; Glipizide; Glyburide; Hypoglycemia; | 1980 |
[Hypoglycemic coma in treatment with glipizide].
Topics: Aged; Glipizide; Humans; Hypoglycemia; Insulin Coma; Male; Middle Aged; Sulfonylurea Compounds | 1982 |
Standardized procedure for the assay and identification of hypoglycemic sulfonylureas in human plasma.
Topics: Chromatography, High Pressure Liquid; Diabetes Mellitus, Type 2; Drug Monitoring; Forensic Medicine; | 1995 |
Factitious hypoglycaemia documented by a modified assay for the measurement of plasma sulphonylurea.
Topics: Adult; Factitious Disorders; Female; Glipizide; Humans; Hypoglycemia; Male | 1995 |
Glucose modulates rat substantia nigra GABA release in vivo via ATP-sensitive potassium channels.
Topics: Adenosine Triphosphate; Analysis of Variance; Animals; Deoxyglucose; gamma-Aminobutyric Acid; Glipiz | 1995 |
Rates of hypoglycemia in users of sulfonylureas.
Topics: Adult; Aged; Chlorpropamide; Female; Gliclazide; Glipizide; Glyburide; Humans; Hypoglycemia; Hypogly | 1997 |
Prospective multicenter study of sulfonylurea ingestion in children.
Topics: Accidents; Administration, Oral; Blood Glucose; Body Weight; Child; Child, Preschool; Confidence Int | 1997 |
Capillary electrophoretic detection of metabolites in the urine of patients receiving hypoglycemic drug therapy.
Topics: Electrophoresis, Capillary; Glipizide; Glyburide; Humans; Hypoglycemia; Sulfonylurea Compounds | 1997 |
Hypoglycemia from glipizide and glyburide.
Topics: Glipizide; Glyburide; Humans; Hypoglycemia; Risk | 1998 |
Hypoglycemia from glipizide and glyburide.
Topics: Aged; Diabetes Mellitus, Type 2; Glipizide; Glyburide; Humans; Hypoglycemia; Risk | 1998 |
Delayed hypoglycemia in a child after ingestion of a single glipizide tablet.
Topics: Antihypertensive Agents; Blood Glucose; Charcoal; Child, Preschool; Glipizide; Glucose; Humans; Hydr | 1998 |
Hypoglycemia. Making a case for glucose gels and tablets.
Topics: Administration, Oral; Diabetes Mellitus, Type 2; Gels; Glipizide; Glucose; Humans; Hypoglycemia; Hyp | 1998 |
Delayed hypoglycemia after ingestion of a single glipizide tablet.
Topics: Adult; Age Factors; Aged; Child, Preschool; Emergency Treatment; Female; Glipizide; Humans; Hypoglyc | 1999 |
Delayed hypoglycemia after ingestion of a single glipizide tablet.
Topics: Age Factors; Child, Preschool; Emergency Treatment; Glipizide; Hospitalization; Humans; Hypoglycemia | 1999 |
Hypoglycemia treatment.
Topics: Administration, Oral; Carbohydrates; Drug Combinations; Gastrointestinal Agents; Glipizide; Glucagon | 1999 |
Diazoxide, glipizide, hypertension and hypoglycaemia.
Topics: Adult; Glipizide; Humans; Hypertension; Hypoglycemia; Male; Sulfonylurea Compounds | 1976 |
Diazoxide, glipizide, and hypoglycaemia.
Topics: Blood Glucose; Diabetes Mellitus; Diazoxide; Drug Antagonism; Glipizide; Humans; Hypoglycemia; Insul | 1977 |
Severe hypoglycaemia during treatment with glipizide.
Topics: Aged; Aged, 80 and over; Diabetes Mellitus, Type 2; Female; Glipizide; Humans; Hypoglycemia; Male; M | 1991 |
A screening test for detecting sulfonylureas in plasma.
Topics: Aged; Aged, 80 and over; Chlorpropamide; Chromatography, High Pressure Liquid; Female; Gliclazide; G | 1990 |
Symptomatic hypoglycemia secondary to a glipizide-trimethoprim/sulfamethoxazole drug interaction.
Topics: Aged; Aged, 80 and over; Blood Glucose; Diabetes Mellitus, Type 2; Drug Interactions; Glipizide; Hum | 1990 |
Possible interaction between heparin and a sulphonylurea a cause of prolonged hypoglycaemia?
Topics: Drug Interactions; Glipizide; Heparin; Humans; Hypoglycemia; Male; Middle Aged; Sulfonylurea Compoun | 1986 |